{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:16:53Z","timestamp":1778879813048,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:14:38Z","timestamp":1774268078000},"page":"381-390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1016","volume":"30","author":[{"given":"Sonal","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paula","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta R.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2026.01.003_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2026.01.003_bib2","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15377","article-title":"Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals","volume":"42","author":"Saponaro","year":"2022","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2026.01.003_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000471","article-title":"Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Behari","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2026.01.003_bib4","article-title":"Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis","volume":"359","author":"Ma","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cld.2026.01.003_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.cld.2026.01.003_bib7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of Nonalcoholic Fatty liver disease and Nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.003_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2337\/dc21-1758","article-title":"Impaired hepatic mitochondrial capacity in nonalcoholic steatohepatitis associated with type 2 diabetes","volume":"45","author":"Gancheva","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2026.01.003_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jhep.2024.08.012","article-title":"Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity","volume":"82","author":"Kahl","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.003_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.003_bib12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in Nonalcoholic Fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2026.01.003_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab"},{"issue":"7785","key":"10.1016\/j.cld.2026.01.003_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.cld.2026.01.003_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2502978122","article-title":"Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis","volume":"122","author":"Sakuma","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.cld.2026.01.003_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ncpendmet0190","article-title":"Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance","volume":"2","author":"Roden","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.cld.2026.01.003_bib19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jhep.2022.08.010","article-title":"Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease","volume":"77","author":"Pafili","year":"2022","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2026.01.003_bib20","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2337\/dc20-0329","article-title":"Role of patatin-like phospholipase domain-containing 3 gene for hepatic lipid content and insulin resistance in diabetes","volume":"43","author":"Zaharia","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.cld.2026.01.003_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.01.003_bib22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","article-title":"\u039cetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","volume":"22","author":"Byrne","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.003_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41574-023-00898-1","article-title":"Inter-organ crosstalk during development and progression of type 2 diabetes mellitus","volume":"20","author":"Xourafa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.cld.2026.01.003_bib25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev-physiol-031622-043133","article-title":"Insulin clearance in health and disease","volume":"85","author":"Najjar","year":"2023","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.003_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.179","article-title":"Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum","volume":"3","author":"Tavaglione","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"10.1016\/j.cld.2026.01.003_bib27","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/hep.26988","article-title":"Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis","volume":"59","author":"Bril","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2026.01.003_bib28","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/dc23-1267","article-title":"Reduced insulin clearance differently relates to increased liver lipid content and worse glycemic control in recent-onset type 2 and type 1 diabetes","volume":"46","author":"Zaharia","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2026.01.003_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ng840","article-title":"CEACAM1 regulates insulin clearance in liver","volume":"30","author":"Poy","year":"2002","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.cld.2026.01.003_bib30","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2024.48","article-title":"Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1","volume":"4","author":"Aldroubi","year":"2024","journal-title":"Metabolism and Target Organ Damage"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2026.01.003_bib31","article-title":"Insights into circulating CEACAM1 in insulin clearance and disease progression: evidence from the Portuguese PREVADIAB2 study","volume":"54 Suppl 2","author":"Patarr\u00e3o","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cld.2026.01.003_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154735","article-title":"Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits","volume":"118","author":"Borges","year":"2021","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.cld.2026.01.003_bib33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1249\/MSS.0000000000002273","article-title":"Exercise training rapidly increases hepatic insulin extraction in NAFLD","volume":"52","author":"Hari","year":"2020","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"10.1016\/j.cld.2026.01.003_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/dc18-1036","article-title":"Insulin clearance after oral and intravenous glucose following gastric bypass and gastric banding weight loss","volume":"42","author":"Shah","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cld.2026.01.003_bib35","article-title":"Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction","volume":"125","author":"Keyhani-Nejad","year":"2020","journal-title":"Peptides (NY)"},{"issue":"10019","key":"10.1016\/j.cld.2026.01.003_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.cld.2026.01.003_bib37","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in Metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cld.2026.01.003_bib38","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.cld.2026.01.003_bib39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.cld.2026.01.003_bib40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cld.2026.01.003_bib41","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.cld.2026.01.003_bib43","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.cld.2026.01.003_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cld.2026.01.003_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.cld.2026.01.003_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/hepr.13645","article-title":"Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"51","author":"Song","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2026.01.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107647","article-title":"The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"213","author":"Li","year":"2025","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.cld.2026.01.003_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2026.01.003_bib49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.003_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2026.01.003_bib51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:58:52Z","timestamp":1778878732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000036"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}